HRP20201793T1 - 1,2,4-triazolo-[3,4-b]-1,3,4-tiadiazol derivati - Google Patents
1,2,4-triazolo-[3,4-b]-1,3,4-tiadiazol derivati Download PDFInfo
- Publication number
- HRP20201793T1 HRP20201793T1 HRP20201793TT HRP20201793T HRP20201793T1 HR P20201793 T1 HRP20201793 T1 HR P20201793T1 HR P20201793T T HRP20201793T T HR P20201793TT HR P20201793 T HRP20201793 T HR P20201793T HR P20201793 T1 HRP20201793 T1 HR P20201793T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- compound according
- methyl
- image
- pyridyl
- Prior art date
Links
- GNSPINPIWPZMKW-UHFFFAOYSA-N [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole Chemical class C1=NN=C2SC=NN21 GNSPINPIWPZMKW-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 15
- -1 oxazinyl Chemical group 0.000 claims 14
- 125000001424 substituent group Chemical group 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- 101100439664 Arabidopsis thaliana CHR8 gene Proteins 0.000 claims 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 125000004306 triazinyl group Chemical group 0.000 claims 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 claims 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 2
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 claims 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims 2
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000000160 oxazolidinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 101100240516 Caenorhabditis elegans nhr-10 gene Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005880 oxathiolanyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (15)
1. Spoj formule (I) ili farmaceutski prihvatljiva sol istog
[image]
gdje
R1 i R2 su isti ili različiti i odabrani su iz grupe koja se sastoji od C1-C5 alkila, fenila, metilfenila,
R3 je odabran iz grupe koja se sastoji od
CH2R8, CH2CH2R8, CH=CHR8, CH2CH2CH2R8, CH2CH=CHR8, CH=CHCH2R8, CH=CH-OR8, CH2-OR8, CH2CH2-OR8, CH=CH-NHR8, CH2-NHR8, CH2CH2-NHR8, CH=CH-SR8, CH2-SR8, CH2CH2-SR8,
[image]
supstituiranog ili nesupstituiranog fenila, benzila, piridila, pirimidinila, triazinila, triazinanila, oksazinila, oksazinanila, cikloeksanila, cikloeksenila, cikloeksadienila, piranila, oksatianila, piperidinila, ciklopentanila, ciklopentenila, ciklopentadienila, pirolidinila, pirolila, furanila, oksazolidinila, pirazolidinila, tiofenila, oksatiinila, oksatiolila, oksatiolanila, gdje supstituent ili supstituenti su odabrani iz grupe koja se sastoji od metila, F, Cl, Br, I, NO2, CN, NH2, OCH2X, CH2X, CX3, CH2CH2X, OH, gdje X je odabran iz grupe koja se sastoji od H, F, Cl, Br, I,
R4, R5, R6, R7 su isti ili različiti i odabrani iz grupe koja se sastoji od H, F, Cl, Br, I, NO2, CN, NH2, OCH3, OH, NHCH2CH3, N(CH3)2,
R8 je odabran iz grupe koja se sastoji od
[image]
supstituiranog ili nesupstituiranog fenila, benzila, piridila, pirimidinila, triazinila, triazinanila, oksazinila, oksazinanila, cikloeksanila, cikloeksenila, cikloeksadienila, piranila, oksatianila, piperidinila, ciklopentanila, ciklopentenila, ciklopentadienila, pirolidinila, pirolila, furanila, oksazolidinila, pirazolidinila, tiofenila, oksatiinila, oksatiolila, oksatiolanila, gdje supstituent ili supstituenti su odabrani iz grupe koja se sastoji od metila, F, Cl, Br, I, NO2, CN, NH2, OCH2X, CH2X, CX3, CH2CH2X, OH, gdje X je odabran iz grupe koja se sastoji od H, F, Cl, Br, I,
R9 je odabran iz grupe koja se sastoji od NHR10, NR11R12,
R10 je odabran iz grupe koja se sastoji od C1-C5 alkila, fenila,
R11 i R12 su isti ili različiti i jesu C1-C5 alkil.
2. Spoj prema patentnom zahtjevu 1, gdje R1 i R2 su isti ili različiti i odabrani su iz grupe koja se sastoji od C1-C3 alkila, fenila, metifenila.
3. Spoj prema patentnom zahtjevu 1 ili 2, gdje R1 i R2 su metil.
4. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, gdje R3 je odabran iz grupe koja se sastoji od CH2R8, CH2CH2R8, CH=CHR8, CH2CH2CH2R8, CH2CH=CHR8, CH=CHCH2R8,
[image]
supstituiranog ili nesupstituiranog fenila, benzila, piridila, gdje supstituent ili supstituenti su odabrani iz grupe koja se sastoji od metila, F, Cl, Br, I, NO2, CN, NH2, OCH2X, CH2X, CX3, CH2CH2X, OH, gdje X je odabran iz grupe koja se sastoji od H, F, Cl, Br, I,
5. Spoj prema bilo kojem od patentnih zahtjeva 1 do 4, gdje R3 je odabran iz grupe koja se sastoji od CH=CHR8, CH2CH2CH2R8,
[image]
supstituiranog ili nesupstituiranog fenila, piridila, gdje supstituent ili supstituenti su odabrani iz grupe koja se sastoji od F, Cl, NO2.
6. Spoj prema bilo kojem od patentnih zahtjeva 1 do 5, gdje R4, R5, R6, R7 su isti ili različiti i odabrani su iz grupe koja se sastoji od H, Cl, Br, I, NH2, OCH3.
7. Spoj prema bilo kojem od patentnih zahtjeva 1 do 6, gdje R4 i R7 su H, R5 i R6 su OCH3.
8. Spoj prema bilo kojem od patentnih zahtjeva 1 do 7, gdje R8 je odabran iz grupe koja se sastoji od
[image]
supstituiranog ili nesupstituiranog fenila, benzila, piridila, gdje supstituent ili supstituenti su odabrani iz grupe koja se sastoji od metila, F, Cl, Br, I, NO2, CN, NH2, OCH2X, CH2X, CX3, CH2CH2X, OH, gdje X je odabran iz grupe koja se sastoji od H, F, Cl, Br, I,
9. Spoj prema bilo kojem od patentnih zahtjeva 1 do 8, gdje R8 je odabran iz grupe koja se sastoji od
[image]
supstituiranog ili nesupstituiranog fenila, piridila, gdje supstituent ili supstituenti su odabrani iz grupe koja se sastoji od F, Cl, NO2.
10. Spoj prema bilo kojem od patentnih zahtjeva 1 do 9, gdje R10 je odabran iz grupe koja se sastoji od C1-C3 alkila, fenila.
11. Spoj prema bilo kojem od patentnih zahtjeva 1 do 10, gdje R10 je metil.
12. Spoj prema bilo kojem od patentnih zahtjeva 1 do 11, gdje R11 i R12 su isti ili različiti i jesu C1-C3 alkil.
13. Spoj prema bilo kojem od patentnih zahtjeva 1 do 12, gdje R11 i R12 su metil.
14. Farmaceutska kompozicija koja sadrži spoj formule (I) prema bilo kojem od patentnih zahtjeva 1 do 13 ili farmaceutski prihvatljiva sol istog i farmaceutski prihvatljiv nosač.
15. Spoj prema bilo kojem od patentnih zahtjeva 1 do 13 ili farmaceutski prihvatljiva sol istog za primjenu u liječenju raka.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20160100380A GR1009565B (el) | 2016-07-14 | 2016-07-14 | Νεα παραγωγα 1,2,4-τριαζολο-[3,4-b]-1,3,4-θειαδιαζολιων |
| PCT/EP2017/067908 WO2018011414A1 (en) | 2016-07-14 | 2017-07-14 | NEW 1,2,4-TRIAZOLO-[3,4-b]-1,3,4-THIADIAZOLE DERIVATIVES |
| EP17742219.3A EP3484892B1 (en) | 2016-07-14 | 2017-07-14 | 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201793T1 true HRP20201793T1 (hr) | 2020-12-25 |
Family
ID=58314472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201793TT HRP20201793T1 (hr) | 2016-07-14 | 2020-11-09 | 1,2,4-triazolo-[3,4-b]-1,3,4-tiadiazol derivati |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10513529B2 (hr) |
| EP (1) | EP3484892B1 (hr) |
| JP (1) | JP7005588B2 (hr) |
| KR (1) | KR102492136B1 (hr) |
| CN (1) | CN109689660B (hr) |
| AU (1) | AU2017296088B2 (hr) |
| CA (1) | CA3030493C (hr) |
| CY (1) | CY1123869T1 (hr) |
| DK (1) | DK3484892T3 (hr) |
| ES (1) | ES2831301T3 (hr) |
| GR (1) | GR1009565B (hr) |
| HR (1) | HRP20201793T1 (hr) |
| HU (1) | HUE051576T2 (hr) |
| LT (1) | LT3484892T (hr) |
| PT (1) | PT3484892T (hr) |
| RS (1) | RS61112B1 (hr) |
| RU (1) | RU2765180C2 (hr) |
| SI (1) | SI3484892T1 (hr) |
| WO (1) | WO2018011414A1 (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7287606B2 (ja) | 2018-08-10 | 2023-06-06 | 株式会社日本スペリア社 | 鉛フリーはんだ合金 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1945648B1 (en) * | 2005-09-21 | 2011-06-08 | Jawaharlal Nehru Centre for Advanced Scientific Research | Derivatives of 4,6-disubstituted 1,2,4-triazolo-1,3,4-thiadiazole, a process and uses thereof |
| WO2007064797A2 (en) | 2005-11-30 | 2007-06-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-met and uses thereof |
| WO2008060578A2 (en) * | 2006-11-15 | 2008-05-22 | Cytovia, Inc. | 3-aryl-6-aryl-[1,2,4] triazolo[3,4-b][1,3,4] thiadiazoles and related compounds as activators of caspases and inducers of apoptosis and the use thereof |
| JP2010528991A (ja) | 2007-05-21 | 2010-08-26 | エスジーエックス ファーマシューティカルズ、インコーポレイテッド | 複素環式キナーゼ調節因子 |
| US8269013B2 (en) * | 2009-05-28 | 2012-09-18 | Vertex Pharmaceuticals Incorporated | Substituted pyrazole inhibitors of c-Met protein kinase |
-
2016
- 2016-07-14 GR GR20160100380A patent/GR1009565B/el active IP Right Grant
-
2017
- 2017-07-14 CA CA3030493A patent/CA3030493C/en active Active
- 2017-07-14 WO PCT/EP2017/067908 patent/WO2018011414A1/en unknown
- 2017-07-14 PT PT177422193T patent/PT3484892T/pt unknown
- 2017-07-14 AU AU2017296088A patent/AU2017296088B2/en active Active
- 2017-07-14 DK DK17742219.3T patent/DK3484892T3/da active
- 2017-07-14 CN CN201780056456.1A patent/CN109689660B/zh active Active
- 2017-07-14 US US16/317,341 patent/US10513529B2/en active Active
- 2017-07-14 JP JP2019501649A patent/JP7005588B2/ja active Active
- 2017-07-14 HU HUE17742219A patent/HUE051576T2/hu unknown
- 2017-07-14 ES ES17742219T patent/ES2831301T3/es active Active
- 2017-07-14 SI SI201730478T patent/SI3484892T1/sl unknown
- 2017-07-14 KR KR1020197003864A patent/KR102492136B1/ko active IP Right Grant
- 2017-07-14 RU RU2019103997A patent/RU2765180C2/ru active
- 2017-07-14 EP EP17742219.3A patent/EP3484892B1/en active Active
- 2017-07-14 RS RS20201367A patent/RS61112B1/sr unknown
- 2017-07-14 LT LTEP17742219.3T patent/LT3484892T/lt unknown
-
2020
- 2020-11-05 CY CY20201101045T patent/CY1123869T1/el unknown
- 2020-11-09 HR HRP20201793TT patent/HRP20201793T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2831301T3 (es) | 2021-06-08 |
| AU2017296088A1 (en) | 2019-02-21 |
| SI3484892T1 (sl) | 2021-01-29 |
| WO2018011414A1 (en) | 2018-01-18 |
| RU2765180C2 (ru) | 2022-01-26 |
| PT3484892T (pt) | 2020-11-05 |
| US20190194228A1 (en) | 2019-06-27 |
| JP7005588B2 (ja) | 2022-02-10 |
| EP3484892B1 (en) | 2020-08-26 |
| RU2019103997A (ru) | 2020-08-14 |
| EP3484892A1 (en) | 2019-05-22 |
| US10513529B2 (en) | 2019-12-24 |
| HUE051576T2 (hu) | 2021-03-01 |
| CA3030493C (en) | 2023-04-04 |
| KR20190030705A (ko) | 2019-03-22 |
| RS61112B1 (sr) | 2020-12-31 |
| JP2019521146A (ja) | 2019-07-25 |
| DK3484892T3 (da) | 2020-11-16 |
| RU2019103997A3 (hr) | 2020-09-30 |
| GR1009565B (el) | 2019-08-06 |
| LT3484892T (lt) | 2021-01-25 |
| CN109689660B (zh) | 2021-08-10 |
| AU2017296088B2 (en) | 2020-10-22 |
| CA3030493A1 (en) | 2018-01-18 |
| CY1123869T1 (el) | 2022-03-24 |
| GR20160100380A (el) | 2018-03-30 |
| KR102492136B1 (ko) | 2023-01-26 |
| CN109689660A (zh) | 2019-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2441869C2 (ru) | Противовирусные соединения | |
| GEP20227433B (en) | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors | |
| HRP20180483T1 (hr) | Spoj kinolona | |
| HRP20171453T1 (hr) | Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za liječenje agregacije trombocita | |
| HRP20180791T1 (hr) | Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b | |
| HRP20191268T1 (hr) | Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk | |
| TW200700387A (en) | 1-benzylindole-2-carboxamide derivatives | |
| HRP20181036T1 (hr) | 2,6-supstituirani derivati purina i njihova upotreba u liječenju proliferativnih poremećaja | |
| PE20191540A1 (es) | DERIVADOS DE PIRROLO [1,2-b] PIRIDAZINA | |
| GEP201606540B (en) | New indolizine derivatives, method for their preparation and pharmaceutical compositions containing thereof | |
| HRP20170311T1 (hr) | Novi spojevi pirolopirimidina kao inhibitori protein kinaza | |
| MX2018003215A (es) | Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2. | |
| HRP20221207T1 (hr) | Supstituirani biciklički heterociklički spojevi kao inhibitori prmt5 | |
| HRP20151410T1 (hr) | Derivati pikolinamida kao inhibitori kinaze | |
| PE20190336A1 (es) | Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| HRP20130861T1 (hr) | 1 h-benzimidazol-4-karboksamidi supstituirani s kvartarnim ugljikom na 2-položaju kao inhibitori parp-a za uporabu u lijeäśenju karcinoma | |
| PE20170127A1 (es) | Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas | |
| MX344276B (es) | Compuesto de piperidina novedoso o sal del mismo. | |
| RS53788B1 (en) | MITOTIC PROGRESSION INHIBITION UNIT | |
| AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
| CY1114318T1 (el) | Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες | |
| HRP20160011T1 (hr) | Imidazopiridazini kao inhibitori akt kinaze | |
| GEP20207128B (en) | Aminothiazole derivatives useful as antiviral agents | |
| HRP20120762T1 (hr) | Tetrasupstituirani piridazini kao inhibitori hedgehog puta | |
| HRP20220263T1 (hr) | Fenil-2-hidroksi-acetilamino-2-metil-fenil spojevi |